Scale or Stall: Cleerly’s $329 Million Validation Blueprint

Cleerly: How Early Validation Drives Funding

Cleerly’s a prime example of how to do cardiac imaging right: get your clinical validation done early. They’ve managed to raise over $329 million through their Series C, which included an extension in December 2024, precisely because they had the data to back up their claims. That funding didn’t just materialize, it’s built on the back of their CERTAIN multicenter trial and its evidence program. CERTAIN multicenter trial details on clinicaltrials.gov Getting big names like the Mayo Clinic involved in the research gives the technology an immediate dose of credibility that’s hard to buy. The trial sites that help generate the evidence often become your first customers, creating a natural sales pipeline that’s far more effective than just sending a sales team to knock on the doors of unfamiliar hospitals. For a cardiac AI SaMD, this kind of early, deep validation is exactly how you de-risk your entry into the market.

HeartFlow: The Long Game of Evidence and a Public Market Payoff

HeartFlow took a different route compared to Cleerly’s focused sprint, playing a much longer game by building out its clinical evidence over many years. This patient, sustained effort paid off with an August 2025 public market listing, coming after they’d raised $364 million and hit a $1.54 billion valuation. SEC EDGAR filing for HeartFlow’s public listing Their journey really shows the long-term rewards of a thorough validation strategy. The company also constructed a dense patent thicket around its CT-FFR technology, proving its commitment to real R&D and the intellectual property that comes from a protracted evidence-gathering program. If you’re an investor trying to size up this niche, HeartFlow’s success is your proof that patiently building a massive body of evidence can translate directly into a huge market cap and a tough-to-beat competitive moat. An extended validation period packed with peer-reviewed publications and real-world evidence (RWE) studies builds a deep well of trust with both the clinicians who use the product and the payers who cover it.

Why Early Validation Creates a Competitive Edge

In the world of AI imaging, the companies that win are the ones that let their trial data speak first. Getting the trial sequence right is about proving clinical utility to the people who actually use the tech and, more importantly, the payers who decide whether to reimburse for it. It’s more than just a regulatory check-box like a 510(k) clearance. A strong validation record, especially from a multicenter trial, gives you the ammunition needed to apply for CPT codes and argue for NTAP reimbursement. That’s how you get paid. When a hospital is considering a new cardiac AI tool and sees it already has a pile of clinical evidence, their perceived risk in adopting it plummets. Hospitals and health systems want to buy technology that’s already demonstrated real outcomes in different clinical environments. It’s simple. Without that proof, even a technically brilliant model will see its adoption stall, and the company risks becoming a zombie in a very crowded market.

For Investors: Make Validation the Center of Due Diligence

If you’re an investor looking at a cardiac AI company, you have to grill them on the timing and depth of their clinical validation. It’s not optional. During due diligence, the data room has to be clean, showing a clear line from the trial programs to the data they generated and the papers that got published as a result. You’ve also got to dig into their GMLP compliance and their QMS (what are they doing to prevent algorithmic drift?), because those foundational systems are what ensure the AI model is reliable and maintains its integrity over its whole lifecycle. This is what separates the cardiac imaging programs that scale from the ones that stall. Companies that finish their clinical validation before their commercial push build a foundation of trust that speeds up adoption and makes a durable funding path possible. Trying to generate that evidence retroactively while you’re also trying to scale sales is a much harder, and usually losing, strategy. The competitive advantage goes to whoever published first and built a substantial evidence base showing the product works in the real world. PubMed search for clinical validation of cardiac AI imaging This isn’t just a good idea. In today’s healthcare AI market, it’s a prerequisite for securing and keeping investment.